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Abstract 
Neuroleptic malignant syndrome and serotonin syndrome are two syndromes whose molecular bases remain poorly understood. The 
phenotypes of both syndromes overlap with other syndromes that have a clear genetic background, in particular RYR1 -related malignant 
hyperthermia. Through a literature review, performed according to the PRISMA guidelines, we aimed to report the clinical features of 
both syndromes, and the results of genetic testing performed. 10 case series and 99 case reports were included, comprising 134 patients. 
A male predominance of 58% was found. The median age was 35 (range 4–84) years. Eight patients experienced recurrent episodes of 
rhabdomyolysis. Genetic analysis was performed in eleven patients (8%), revealing four RYR1 variants, three likely benign (p.Asp849Asn, 
p.Arg4645Gln, p.Arg4645Gln) and one variant of uncertain significance (p.Ala612Thr). This review underlines that a subset of patients with 
neuroleptic malignant syndrome and serotonin syndrome develop recurrent episodes of rhabdomyolysis. This recurrent pattern suggests a 
possible underlying (genetic) susceptibility. However, the genetic background of neuroleptic malignant syndrome and serotonin syndrome 
has only been investigated to a very limited degree so far. The increasing availability of next generation sequencing offers an opportunity to 
identify potentially associated genetic backgrounds, especially in patients with recurrent episodes or a positive family history. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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1. Introduction 
Rhabdomyolysis is a severe and potentially life-threatening 
medical emergency involving the dissolution of skeletal 
muscle cells, due to a wide range of etiologies that 
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ultimately all converge in a common pathway leading to 
irreversible muscle breakdown [1] . Whilst in some instances 
rhabdomyolysis may be exclusively due to external triggers 
(e.g., trauma, local ischaemia, exertional exercise), recent 
observations suggest that such events more commonly reflect 
a synergistic effect of predisposing genetic and environmental 
factors [2] . Specific phenotypes elicited by pharmacological 
agents (malignant hyperthermia (MH), neuroleptic malignant 
syndrome (NMS) and serotonin syndrome (SS)) feature 
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muscle breakdown as an essential part of a more widely 
defined syndrome, and are all considered part of the 
rhabdomyolysis spectrum. 
MH is a well described pharmacogenetic disorder 
which clinically manifests as a hypermetabolic crisis 
when an MH-susceptible (MHS) individual is exposed 
to volatile anesthetics ( e.g., halothane, isoflurane, 
sevoflurane, desflurane) or the depolarizing muscle relaxant 
succinylcholine. An MH reaction typically features a critically 
increased body temperature (often in excess of 42 °C), muscle 
rigidity or spasms, rhabdomyolysis, tachycardia, and other 
life-threatening symptoms. MH has been associated with 
specific mutations in the RYR1, CACNA1S or STAC3 genes, 
all of which ultimately result in excessive cytoplasmic 
calcium accumulation in response to both pharmacological 
and non-pharmacological triggers. To date, 48 RYR1 and two 
CACNA1S variants have been unequivocally classified as MH 
diagnostic variants ( https:// www.emhg.org/ genetics ). 
In contrast to MH, the genetic background and 
pathophysiology of NMS or SS are relatively poorly 
understood. SS is a potentially fatal condition, most likely 
caused by high levels of serotonin (5-hydroxytryptamine, 
5-HT) in the synaptic cleft, leading to an overactivation of 
the central and peripheral serotonin receptors. The reaction is 
thought to be concentration dependent, and is often the result 
of concomitant exposure to two or more serotonergic agents. 
Monoamine oxidase inhibitors, selective serotonin reuptake 
inhibitors, and serotonin-norepinephrine reuptake inhibitors 
are the medications most commonly associated with SS 
[3] . Simultaneous prescription of medication inhibiting the 
cytochromes P450 (CYPs) is associated with increased serum 
concentration of serotonergic drugs, leading to potentially 
toxic levels. Similarly, genetic polymorphisms in these CYP 
enzymes, in particular CYP2D6, CYP3A4, and CYP2C19, 
increase the serum concentration of serotonergic medication 
and thus the risk of reaching a potentially toxic serum 
concentration [4] . In addition, it appears that polymorphisms 
in the 5-HT-2A receptor may predispose to the development 
of SS [5] . 
NMS is most likely caused by impaired function of central 
dopamine pathways [6] . This hypodopaminergic theory is 
based on the observation that NMS typically develops 
after exposure to dopamine antagonists, or acute withdrawal 
of dopamine agonists, referred to as the neuroleptic 
malignant-like syndrome (NMLS) [7] . NMS is a rare but 
potentially life-threatening reaction to almost any of a group 
of antipsychotic drugs or major tranquilizers (neuroleptics). 
A genetic basis for the disorder had been suspected but has 
not been proven yet; a case series of identical twins, and a 
mother and two daughters all experiencing NMS, support this 
suspicion of an underlying genetic risk factor [8] . 
Some authors have suggested that NMS may be genetically 
related to MH [9-11] , taking into account that the clinical 
triad of autonomic dysfunction, altered mental status and 
rhabdomyolysis is seen in both MH and NMS, but 
also SS. The hypothesis of RYR1 involvement in NMS 
and SS is also supported by the observation that other 
similar (non-anesthesia) related clinical syndromes with 
rhabdomyolysis such as exertional heat stroke (EHS) and 
exertional rhabdomyolysis (ERM) have also been associated 
with (MH-related) RYR1 variants [12] . The overlap in clinical 
presentation and pathophysiological pathways suggests that 
there might be similarities between the genetic background 
underlying MH/ERM/EHS and NMS/SS. 
In the present study we aim to review the clinical features 
of patients with hyperCKemia or rhabdomyolysis events in 
the context of NMS and SS. In addition, we aim to describe 
genetic testing (where performed) in particular in patients 
with clinical features suggestive for a monogenic background 
(i.e. , recurrent episodes or a positive family history). 
2. Methods 
A systematic review was performed according to the 
guidelines of “Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses” (PRISMA) [13] . Methods of the 
analysis and inclusion criteria were specified in advance and 
documented in a permanent record in Prospero (Registration 
number CRD42018115828). 
Cohort studies, case control studies, case reports and case 
series were included. No publication date or publication 
status restrictions were imposed. Patients of any age were 
included if a diagnosis of rhabdomyolysis was made and in 
addition the diagnosis of NMS or SS was considered definite 
or probable. A separate search was performed on all cases 
of rhabdomyolysis induced by the use of the recreational 
drug 3,4-methylenedioxymethamphetamine (MDMA/ecstasy), 
since not all literature considers this as a specific form of 
SS [14] . In cases where CK levels were unknown, or serum 
CK levels did not exceed 1.5 times the upper limit of normal 
(ULN), the study was excluded as not fulfilling the diagnostic 
criteria for hyperCKemia ( > 1.5x ULN) or rhabdomyolysis 
( > 10x ULN) [15] . Meta-analyses, review articles, conference 
abstracts, articles not in English, animal studies, and studies 
of which no full-text was available, were also excluded. 
A literature search was performed in MEDLINE, 
EMBASE, Psycinfo and the Cochrane Library from inception 
to January 31, 2019. The following keywords and all 
known synonyms for these keywords were used: ‘Neuroleptic 
malignant syndrome’, ‘Serotonin syndrome’, ‘MDMA’, 
‘Rhabdomyolysis’. In addition, based on clinical similarities 
and in particular considering rhabdomyolysis as a shared 
clinical endpoint, we conducted an additional search for 
RYR1 , given that the part of the NMS- and SS-related 
rhabdomyolysis spectrum is possibly associated with RYR1 
variants. The search strategy is detailed in Appendix 1. 
Eligibility assessment was performed by two independent 
reviewers (N.K, J.W) in an unblinded standardized manner. 
Each study was reviewed for eligibility based on title and 
abstract. The full text of presumably eligible studies was 
evaluated to decide whether the study fulfilled the inclusion 
criteria. In case of discrepancies between the two reviewers, 
consensus was reached after discussion; if no agreement could 
be reached, a third reviewer was consulted. 
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Fig. 1. Flow diagram of the study selection process. 
We developed a data extraction sheet, which was 
then pilot-tested on ten randomly-selected included studies, 
and subsequently refined accordingly. One review author 
(N.K.) extracted the data items from included studies. 
Information was extracted from each included study on 
(1) clinical characteristics (including age, sex, medical 
history, family history, temperature and mental status 
during the episode); (2) laboratory results (including 
peak CK levels, myoglobinuria, genetic testing); (3) 
neurological symptoms and examination (including myalgia, 
muscle cramps/weakness/swelling, extrapyramidal symptoms, 
hyperreflexia, clonus); (4) outcome (including recurrence, 
death). The number of episodes was divided into three groups: 
recurrent, non-recurrent and unknown. If multiple episodes of 
rhabdomyolysis were reported in one patient, the first episode 
was used for describing the data. 
Based on our experience with exertional rhabdomyolysis, 
the following clinical features were considered suggestive for 
a monogenic background: 1) recurrent rhabdomyolysis and/or 
2) a positive family history of neuromuscular disorders, in 
particular MH and rhabdomyolysis [16] . 
Categorical data were compared using the χ2 test, or Fisher 
exact test in case of less than 5 patients. Continuous variables 
were compared using the Mann-Whitney U test. 
3. Results 
The search yielded a total of 1206 studies. After removal 
of duplicates, 976 studies remained. After reviewing the titles 
and abstracts, 699 studies were excluded because they did 
not meet the eligibility criteria. The full text of the remaining 
277 studies was examined in more detail. It appeared that 168 
citations did not meet the inclusion criteria ( Fig. 1 ). 
3.1. Study characteristics 
A total of 109 studies (10 case series and 99 case reports) 
were included, comprising 143 cases of which 134 cases met 
our inclusion criteria. These included 60 cases of SS- and 74 
cases of NMS-related rhabdomyolysis. 
3.2. Clinical features 
Characteristics of the patients are described in Table 1 . 
The median age was 35.0 years (range, 4–84). 77 (58%) 
were male, 57 (43%) were female. Death was reported in 
23 patients (17%). In eight patients, rhabdomyolysis was 
recurrent (6%). Myoglobinuria was reported in 38 patients 
(27%). Results of the neurological examination during the 
episode of rhabdomyolysis are listed in Table 2 . 
3.2.1. Serotonin syndrome 
A total of sixty patients with SS, 33 male and 27 female, 
were included. Those patients had a median age of 23 years 
(range 4–75). The median maximum temperature during the 
episode was 39.5 °C (range 35.4–43.3). The median peak 
CK level was 10,888 (range 354–196,000 IU/l). Thirty three 
cases could be attributed to the prescription of a specific 
medication, twenty seven cases (45%) involved SS due to 
intoxication with MDMA. Patients with MDMA intoxication 
were younger than patients in whom medication was 
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Table 1 
Patient characteristics and etiology. 
Neuroleptic 
malignant syndrome 
( n = 74) 
Serotonin 
Syndrome 
( n = 60) 
Total ( n = 134) p -value 
n (%) n (%) n (%) 
Etiology 
Medication 74 (100.0) 33 (55.0) 107 (78.7) –
MDMA – 27 (450) 27 (21.3) 
Sex 
Male 44 (59.5) 33 (55.0) 77 (57.5) 0.604 
Female 30 (40.5) 27 (45.0) 57 (42.5) 
Age 
Median ∗ 45.0 (9–84) 23.0 (4–75) 35.0 (4–84) < 0.001 
Average ∗∗ 45.5 (17.93) 28.3 (15.34) 37.7 (18.81) 
Peak CK (IU/L) 







Average ∗∗ 30,181 (41,823) 24,401 
(37,553) 
27,593 (39,925) 
ULN 1.5 – 10x 12 (16.2) 8 (13.3) 20 (15.0) 
ULN > 10x 62 (83.8) 52 (86.7) 114 (85.0) 
Max temp ( °C) (n = 72) (n = 56) (n = 128) 
Median ∗ 39.5 (35.4–42.8) 39.5 
(35.4–43.3) 
39.5 (35.4–43.3) 0.535 
Average ∗∗ 39.6 (1.66) 39.7 (2.00) 39.7 (1.81) 
Max temp > 38.5 °C 
Yes 52 (70.3) 44 (73.3) 96 (71.6) 0.286 
No 22 (29.7) 12 (20.0) 34 (25.4) 
Not reported – 4 (6.7) 4 (3.0) 
Recurrent 
Recurrent 6 (8.1) 2 (3.3) 8 (6.0) 0.296 
First episode 44 (59.5) 12 (20.0) 56 (41.8) 
Not reported 24 (32.4) 46 (76.7) 70 (52.2) 
Mental status 
Normal 2 (2.7) 1 (1.7) 3 (2.2) –
Comatose 26 (35.1) 18 (30.0) 44 (32.8) 
Agitated 16 (21.6) 20 (33.3) 36 (26.9) 
Confused 15 (20.3) 9 (15.0) 24 (17.9) 
Elevated mood 1 (1.4) – 1 (0.7) 
Altered 8 (10.8) 1 (1.7) 9 (6.7) 
Not reported 6 (8.1) 11 (18.3) 17 (13.7) 
Outcome 
Dead 15 (20.3) 8 (13.3) 23 (17.2) 0.148 
Alive 46 (62.2) 49 (81.7) 95 (70.9) 
Not reported 13 (17.6) 3 (5.0) 16 (11.9) 
Drug overdose 
Yes † 3 (4.1) 39 (65.0) 19 (14.2) < 0.001 
No 71 (95.9) 21 (35.0) 115 (86.8) 
Relevant family 
history 
Positive – – – –
Negative 3 (4.1) 2 (3.3) 5 (3.7) 
Not reported 71 (95.9) 58 (96.7) 129 (96.3) 
Values are depicted as ∗ median (range) and ∗∗ average (standard deviation), † auto-intoxication including all patients with MDMA intoxication. 
Abbrevations: CK = creatine kinase, MDMA = methylenedioxymethamfetamine, ULN = upper limit of normal. 
prescribed (23.4 compared to 34.7 years, p < 0.001). Twelve 
patients (20%) had attempted suicide through overdosing 
with antidepressant medication. Hyperreflexia was more often 
reported as a key feature in SS compared to NMS (37% vs. 
4.1%, p = 0.020). In addition, convulsions were reported more 
often in patients with SS (47%, p = 0.026). 
3.2.2. Neuroleptic malignant syndrome 
In the group of 74 patients with NMS, 44 were male 
and 30 were female; they had a median age of 45 years 
(range 9–84). Patients had a median maximum temperature 
of 39.5 °C (range 35.4–42.8). The median peak CK level was 
15,059 IU/L (range 572–220,000). Rigidity was reported more 
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Table 2 
Results of the reported neurologic symptoms and examination. 
Neuroleptic malignant syndrome (n = 74) Serotonin syndrome (n = 60) p -value 
Neurological 
examination 
Yes (%) No (%) Yes (%) No (%) 
Myalgia 4 (5.4) – 8 (13.3) 2 (3.3) 0.495 
Muscle weakness 5 (6.8) – 6 (10.0) – –
Muscle swelling 1 (1.4) 1 (1.4) 4 (6.7) – –
Tremor 12 (16.2) 1 (1.4) 15 (25.0) – 0.464 
Diaphoresis 23 (31.1) 2 (2.7) 17 (28.3) – 0.348 
Increased tone 10 (13.5) 3 (4.1) 6 (10.0) 2 (3.3) 0.656 
Rigidity 54 (73.0) 4 (5.4) 17 (28.3) 5 (8.3) 0.059 
Myoclonus 3 (4.1) 1 (1.4) 19 (31.7) – 0.174 
Hyperreflexia 3 (4.1) 2 (2.7) 22 (36.7) 1 (1.7) 0.020 
Clonus – – 14 (23.3) 1 (1.7) –
Convulsions 5 (6.8) 3 (4.0) 28 (46.7) 1 (1.7) 0.026 
Table 3 
Characteristics of the group of patients experiencing recurrent episodes of 
NMS and/or SS compared to patients with a single episode. Temperature 
involved the maximum temperature measured during the rhabdomyolysis 
episode. 
Recurrent episode 
(n = 8) n (%) 
Single episode 
(n = 126) n (%) 
p -value 
Syndrome 
NMS 6 (75.0) 68 (54.0) 0.296 
SS 2 (25.0) 58 (46.0) 
Sex 
Male 4 (50.0) 73 (57.,9) 0.723 
Female 4 (50.0) 53 (42.1) 
Age ∗ 43.5 (20–70) 33.5 (4–84) 0.280 





Temperature ∗ 38.2 (35.4–41.2) 39.5 (35.4–43.3) 0.059 
Fever 
Yes 3 (37.5) 93 (73.8) 0.029 
No 5 (62.5) 29 (26.2) 
Mental status 
Normal 1 (12.5) 2 (1.6) 
Comatose 3 (37.5) 41 (32.5) 
Agitated 2 (25.0) 34 (27.0) 
Confused 1 (12.5) 23 (18.3) 
Elevated mood – 1 (0.8) 
Altered – 9 (7.1) 
Not reported 1 (12.5) 16 (12.7) 
Outcome death 
Yes 2 (25.0) 21 (16.7) 0.332 
No 4 (50.0) 91 (72.2) 
Not reported 2 (25.0) 14 (11.1) 
∗ indicated as median (range). 
Abbrevations: CK = creatine kinase, NMS = neuroleptic malignant syndrome, 
SS = serotonin syndrome. 
commonly in patients with NMS compared to SS (73% vs. 
28%, p = 0.053) 
3.3. Presumed genetic susceptibility and genetic screening 
Table 3 shows the characteristics of the subset of eight 
patients experiencing recurrent episodes of NMS and/or SS. 
Table 4 shows the characteristics of the individual cases. 
Genetic testing was performed in one case report and one 
case series, comprising eleven patients (8%). 
3.3.1. Serotonin syndrome 
Out of 60 patients with SS, two patients developed 
recurrent episodes of rhabdomyolysis. Both patients 
developed SS and also had experienced an episode of 
NMS in their history or at follow up (patients 1 and 2, 
Table 4 ). Of these, genetic screening was performed in 
one patient. This patient, a 20-year-old woman, developed 
rhabdomyolysis after exposure to MDMA [17] . Two weeks 
later, she developed NMS after being exposed to haloperidol. 
Performing both RT-PCR, covering the complete RYR1 
transcript, and sequence analysis of genomic DNA, a 
presumed pathogenic variant in the RYR1 gene was revealed 
(c.2545G > A in exon 20 resulting in an amino acid change 
p.Asp849Asn). Her asymptomatic mother carried the same 
variant and was considered MH negative after caffeine- 
halothane contracture testing. 
3.3.2. Neuroleptic malignant syndrome 
Recurrent episodes of rhabdomyolysis due to NMS were 
reported in six patients (patients 3–8, Table 4 ). Seven 
patients had experienced an adverse drug reaction (other than 
rhabdomyolysis) to antipsychotics in their history. One case 
series included limited RYR1 genetic testing in ten patients 
with NMS. Six RYR1 variants known to be associated with 
malignant hyperthermia were analyzed, with negative test 
results. However, comprehensive RYR1 screening was not 
performed [10] . 
In 129 cases (96%) no information regarding family history 
was provided, and five patients mentioned a negative family 
history. In one patient, a debatable positive family history 
involved an asymptomatic mother carrying a RYR1 variant 
(patient 1, Table 4 ). 
4. Discussion 
This systematic review identified 109 studies fulfilling 
the selection criteria, comprising 74 cases of NMS and 60 
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Table 4 
Characteristics of individual patients with recurrent episodes of rhabdomyolysis. 
# Syn- 
drome 
Author (year) Sex, 
age 




Medication (time after first 
administration) 
Regime, outcome Additional information 
1 SS Russell 
(2012) [17] 
F, 20 1 > 20,000 41.0 Unknown quantity MDMA 
(24 h) 
Supportive care, resolution 
rhabdomyolysis 
RYR1 analysis: 
c.2545G > A 
p.Asp849Asn in exon 20 
2 > 30,000 39.5 NR Treatment with dantrolene, 
resolution of CK-levels 
3 > 11,124 40.9 Haloperidol (NR) Discontinuation of haloperidol 
and active cooling, improvement 
and discharge on day 42 
2 SS Rajapakse 
(2010) [35] 
M, 43 1 170,800 41.2 Venlafaxine (2 weeks) Bicarbonate hemodialysis and 
discontinuation venlafaxine, 
normalization of CPK within 2 
weeks 
Possible episode of NMS 
after administration of a 
phenothiazine six months 
earlier 
3 NMS Aggarwal 
(2014) [36] 
M, 23 1 23,614 38.0 Paliperidone 9 mg d.d.(2 
weeks) 
Intravenous hyperhydration and 
discontinuation paliperidone 
2 10,487 37.2 Ziprasidone 60 mg 2d.d. (2 
weeks) Lithium 900 mg d.d. 
(2 weeks) 
i.v. hyperhydration and 
discontinuation ziprasidone, 
lithium for 3 weeks 
3 994 37.4 Haloperidol 5 mg d.d 
Benztropine 1 mg 2d.d. (3 
weeks) 
i.v. hyperhydration and 
discontinuation haloperidol 
4 1493 NR Quetiapine 100 mg 2d.d. (7 
days) 
Ceasing quetiapine, start 
olanzapine. No adverse effects 
reported after 2 months 
4 NMS Mohan 
(2014) [37] 
M, 48 1 1344 35.4 Quetiapine (unknown) Discontinuation quetiapine, 
normalization CK 
2 1263 NR Aripiprazole (10 days) Discontinuation aripiprazole, 
normalization CK 
3 25,810 NR Amisulpride (5 years) Discontinuation amisulpride, 
normalization CK 
4 9728 NR Olanzapine (5 years) Discontinuation amisulpride, 
normalization CK, No adverse 
effects reported after start 
clozapine, 
5 NMS San Gabriel 
(2015) [38] 
M, 42 1 27,847 38.3 Olanzapine 20 mg d.d.(10 
years) Clozapine 1 mg 3d.d. 
(unknown) Haloperidol 
cumulative: 5 mg 
p.o. + 15 mg i.m. and 100 mg 
chlorpromazine i.m. 
i.v. hyperhydration and 
discontinuation neuroleptics, 
resolution of CK-levels 
2 200,000 NR Quetiapine 100 mg d.d. (16 
days) 
i.v. hyperhydration and 
discontinuation quetiapine, 
resolution of CK-levels 
3 27,966 NR Clozapine (20 days) Discontinuation of clozapine, 10 
ECT sessions, discharge 
6 NMS Cooper 
(2009) [39] 
F, 60 1 754 37.9 Periciazine 10 mg a.n. (3 
weeks) 
Treatment with bromocriptine, 
resolution of symptoms. ECT 
for persistent catatonia 
Co-ingestion of 
simvastatin 
2 884 37.5 Quetiapine 125 mg d.d. (4 
weeks) 
Discontinuation simvastatin, 
resolution of symptoms 
7 NMS Allsop 
(1987) [40] 
F, 44 1 > 10,000 NR Fluphenthixol depot (4 
weeks) 
Treatment with dantrolene 
20 mg 3 times daily, death due 
to gastrointestinal bleeding 
complicated by intravascular 
coagulation 
A similar episode had 
occurred 5 years earlier 
8 NMS Jones 
(1989) [41] 
F, 70 1 3300 39.4 Chlorpromazine 25 mg 3d.d. 
(NR) Isocarboxazid 10 mg 
(NR) 
Discontinuation neuroleptics, 
improvement within 24 h 
Six occasions of 
unexplained confusional 
state with rigidity and 
autonomic dysfunction in 
the last two years 
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Fig 2. Summary of the clinical phenomenology of the Serotonin syndrome and Neuroleptic malignant syndrome. 
cases SS associated with hyperCKemia or rhabdomyolysis. 
In both subsets, a male predominance of 60% (NMS) and 
55% (SS) was found. Cases with SS more often involved an 
auto-intoxication with medication (20%) or recreational drugs 
(45%) than cases with NMS (4%) ( p < 0.001), reflecting 
that SS is a concentration-dependent syndrome and NMS 
is considered an idiosyncratic reaction [18] . Eight patients 
experienced recurrent episodes of rhabdomyolysis. Those 
involved six patients with recurrent NMS, and two patients 
with SS that had experienced NMS at different timepoints. 
Many of the clinical characteristics of both syndromes 
overlap. It has been discovered that the pathways of serotonin 
and dopamine are very much intertwined, and it may be 
therefore that symptoms associated with both SS and NMS 
are reflected by a final shared pathway [19] . However, 
hyperreflexia and convulsions were reported more often in 
patients with SS, both features supportive of central origin. A 
summary of the clinical phenomenology of both syndromes 
is depicted in Fig. 2 . 
The mean age in our subset of patients with NMS is 
similar to the average median age of 39 years found in 
a recent systematic review involving also NMS patients 
without rhabdomyolysis [20] . The age of patients with SS 
in our review is below the mean age of 58 found in 
a large French retrospective study, also after separating 
MDMA-induced SS from medication induced SS (mean ages 
of 23 and 35, respectively) [21] . For both NMS and SS, 
the mean age was higher compared to the age of onset in 
patients with MH, experiencing a first adverse reaction at a 
mean age of 18 years [22] . Presumably, this is due to the 
prescription of antipsychotics and antidepressants at an older 
age, or the prescription of multiple neuroleptics at a higher 
age, compared to potentially MH-triggering anaesthetics and 
muscle relaxants that are administered throughout lifetime, or 
even preferentially in the pediatric age group. 
The male preponderance seen in our review is also 
observed in malignant hyperthermia, not in keeping with 
what is expected in a strictly monogenic autosomal-dominant 
disorder [ 23 , 24 ]. It has been previously hypothesized that the 
male predominance in MH was caused by men being more 
frequently exposed to types of surgery commonly associated 
with MH. However, a study on in vitro contracture test 
(IVCT) outcome reported a significant difference in sex 
distribution, with males revealing a positive IVCT more 
frequently [24] , probably reflecting additional hormonal or 
other sex-dependent variables. In addition, there is a higher 
use of antipsychotics in men compared to women, and men 
are known also to adhere to medication more consistently 
[25] . Also, in a study on acute intoxications in six Dutch 
hospitals, intoxications due to substance abuse was more 
frequently seen in men (66.0%) [26] . 
The mortality rate in both subsets of patients was 20% 
(NMS) and 13% (SS), respectively. Mortality rates in MH 
have decreased from 80% thirty years ago, to < 5% in 
2006 [23] , because of the introduction of Dantrolene into 
pharmacological MH management. In more recent studies in 
our cohort, less deaths were reported in both groups (mortality 
of 13% from 2000 to 2018, 27% from 1984 to 1999). 
The cumulative recurrence rate of 6% in our present study 
(8% in NMS and 3% in SS) is lower than in studies on 
rhabdomyolysis in general. In a retrospective study performed 
in 2005, 475 hospitalized patients with rhabdomyolysis were 
described, reporting a recurrence rate of 11% in a group 
with various etiologies [27] . A subgroup analysis of 38 NMS 
patients in this study revealed a recurrence rate of 25%. No 
investigations into possible underlying genetic susceptibilities 
were performed in these subjects. In 56% of all cases in 
our study, information on possible previous episodes in the 
patient’s medical history was lacking, likely pointing to an 
underestimation of recurrence rates. In patients with recurrent 
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Table 5 
Overview of genetic testing in patients with episodes of rhabdomyolysis due to psychiatric agents in our present study, and previous studies. 
Study Nucleotide Protein Pathogenicity 
Russell, 2012 c.2545G > A p.Asp849Asn Likely benign, not evolutionary conserved (Ser-or 
Ala-in other vertebrates) 
Miyatake, 1996 c.7281C > T p.Ala2427 = Likely benign, silent variant present in 10% of the 
Asian population 
Sato, 2010 c.13934G > A p.Arg4645Gln Likely benign, not evolutionary conserved (Tyr, Ala, 
Ser-or Thr-in other vertebrates) 
detected in one person with MHS 
NR p.Ala612Thr Variant of uncertain significance 
Dlamini, 2013 NR p.Tyr2426Cys Variant of uncertain significance, 
NR 
p.Thr4288_Ala4290dup 
Variant of uncertain significance 
Abbrevations: NR = Not reported. 
episodes, no discernable factors (for example, presence of 
intercurrent illness, fever, exercise) were reported that may 
have modified the presentation. 
The mother of patient 1 carried the same RYR1 variant 
(c.2545G > A in exon 20 resulting in an amino acid change 
p.Asp849Asn) but was tested negative for caffeine-halothane 
contracture testing (CHCT), leading the authors to conclude 
that the RYR1 variant was non-contributory to the phenotype. 
However, a recent study shows that the majority of patients 
with ERM related to pathogenic RYR 1 variants had a negative 
CHCT (or in vitro contracture test (IVCT)), indicating that 
these tests do not have the same discriminatory value for 
RYR1 -related rhabdomyolysis as for RYR1 -related MH [28] . 
Interestingly, a case report published in 2003 reported a 
patient with NMS in whom contracture testing with caffeine 
and halothane was negative, but in an analogous setting, the 
patients isolated muscle was found to react pathologically 
towards contracture testing with neuroleptics [29] . 
We also identified additional cases in the literature 
in whom rhabdomyolysis was triggered by exposure to 
antipsychotics, but who were not diagnosed as NMS or 
SS and were therefore not included in the current review. 
These patients are summarized in Table 5 . Dlamini et al. 
sequenced RYR1 in 39 unrelated families with rhabdomyolysis 
and identified 9 heterozygous variants in 14 families [2] . 
Two patients were on olanzapine treatment at the time of 
presentation with rhabdomyolysis. In both patients, a RYR1 
variant was found, one of which the authors mentioned to be 
associated with MH (p.Tyr2426Cys). However, to date, the 
relation of this variant with MH remains unclear, although 
it localizes to the MH mutational hotspot affecting the 
central domain of the RyR1 protein. The second patient 
on olanzapine treatment involved the p.Thr4288_Ala4290dup 
variant, that has been reported in three MHS individuals 
of which two also had a history of exercise induced 
rhabdomyolysis. Since all these individuals also had a second 
RYR1 variant, the specific role of the p.Thr4288_Ala4290dup 
in MH and rhabdomyolysis remains uncertain [30] . 
In 2010, Sato et al. performed post mortem genetic analysis 
on eleven psychiatric patients who died of hyperthermia, most 
likely caused by NMS [31] . This paper was not included 
in our quantitative data-analysis because it did not report 
CK levels. Two patients carried a RYR1 variant resulting in 
an amino acid change: 1) p.Arg4645Gln, a variant probably 
not pathogenic, based on evolutionary conservation, and 2) 
p.Ala612Thr, a substitution affecting a conserved amino acid 
residue that might have plausibly contributed to the event 
of rhabdomyolysis, regarding its location near the common 
p.Arg614Cys diagnostic MH variant. 
To our knowledge, this is the first literature review 
describing all reported patients with hyperCKemia or 
rhabdomyolysis in the context of NMS and SS. However, the 
quality of data obtained from most reports was considered 
low; neurological examination was often not or only 
incompletely described, resulting in a substantial amount of 
missing data. In addition, information regarding recurrent 
episodes family history, or genetic testing was often absent. 
Therefore, it is impossible to ascertain if or if not some 
clinical characteristics were not present, or if the author 
decided not to describe a negative test result. Furthermore, 
only few studies included information concerning the patient’s 
medical and family history. 
Genetic testing was performed in only a small amount of 
studies of patients (8%). Therefore, based on the currently 
available data, there is little evidence to suggest that all 
patients should undergo genetic testing, however, these 
recommendations may change if additional information based 
on more comprehensive genetic testing in such cohorts 
becomes available. Although highly desirable, considering 
the comparative rarity of these presentations, performing a 
prospective study is not feasible. Based on the results in our 
present study we would advise to perform additional genetic 
testing, for example through an NGS-based rhabdomyolysis 
panel, in patients with drug-induced rhabdomyolysis and 
features suggestive of genetic susceptibility, such as a 
positive family history or recurrent episodes. To inform 
such an approach, it is, firstly, important to recognize 
specific genotype-phenotype correlations of genetic disorders 
associated with rhabdomyolysis to further determine the 
diagnostic approach, and to decide which candidate genes are 
opportune for testing [32] . Secondly, although the RYR1 gene 
is a likely candidate for these presentations, RYR1 is also 
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an extraordinarily complex gene with over 5000 amino acid 
residues that harbors many, often common missense variants 
(over 2000 already known) [33] . Performing next generation 
sequencing on a large gene such as RYR1 will therefore in 
all likelihood reveal a large number of variants of unknown 
significance. Although RYR1 analysis therefore requires a 
very careful and informed approach, in our view RYR1 
sequencing should be considered in particular in patients with 
recurrent episodes, considering the presence of RYR1 variants 
in a proportion of the patients with NMS- or SS-related 
rhabdomyolysis we found in our literature review. 
Identification of the genetic background implicated in 
these pharmacogenetic syndromes is important for several 
reasons. Firstly, in line with a personalized medicine 
approach, an informed decision can be made to avoid certain 
pharmacological agents in individuals where those may be 
harmful due to a specific genetic predisposition. Secondly, 
specific measures may be taken (for example, prescription 
of the specific ryanodine receptor antagonist Dantrolene in 
cases where RYR1 has been implicated) to prevent recurrent 
episodes [34] . Thirdly, in cases where diagnostic MH variants 
in RYR1 have been identified, genetic counseling of the 
patient and their families may prevent life-threatening MH 
events. The potential to identify the genetic background of 
NMS and SS has massively increased in recent years, due to 
the increasing availability of next generation sequencing, but 
appears not to have been fully utilized yet in these conditions. 
5. Conclusion 
Many of the clinical characteristics of SS and NMS 
overlap, except for hyperreflexia and convulsions (SS) and 
rigidity (NMS). This review underlines that a subset of 
patients develop recurrent episodes of rhabdomyolysis during 
NMS or SS, or both syndromes during different timepoints, 
suggesting a possible underlying (genetic) susceptibility. 
The genetic background of NMS and SS has been 
investigated only to a very limited degree so far, but the 
increasing availability of next generation sequencing offers 
an opportunity to identify potentially associated genetic 
backgrounds, especially in patients with a positive family 
history or recurrent episodes. 
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Appendix 
A: search strategy 
Search PubMed 
1 Neuroleptic Malignant Syndrome[Mesh] 
2 Neuroleptic malignant syndrome ∗[tiab] 
3 malignant neuroleptic syndrome ∗[tiab] 
4 Antipsychotic malignant syndrome ∗[tiab] 
5 malignant antipsychotic syndrome ∗[tiab] 
6 NMS [tiab] OR NMSs [tiab] 
7 1 or 2 or 3 or 4 or 5 or 6 
8 Serotonin Syndrome[Mesh] 
9 Serotonin syndrome ∗[tiab] 
10 Serotonin Uptake Inhibitors/adverse effects[MeSH] 




15 Ecstasy [tiab] OR XTC [tiab] 
16 3,4-Methylenedioxyamphetamine/analogs and 
derivatives[Mesh] 





22 hyperCK ∗[tiab] 
23 18 or 19 or 20 or 21 or 22 
24 Ryanodine Receptor Calcium Release Channel[Mesh] 
25 Ryanodine Receptor ∗[tiab] 
26 RyR1[tiab] 
27 24 or 25 or 26 
28 7 or 11 or 17 
29 23 or 27 
30 28 and 29 
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